发明公开
EP2307387A1 NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE
有权
新HETERCYCLISCHE化合物用于治疗心血管疾病的治疗
- 专利标题： NOVEL HETEROCYCLYL COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASE
- 专利标题（中）： 新HETERCYCLISCHE化合物用于治疗心血管疾病的治疗
-
申请号： EP09780158.3申请日： 2009-07-06
-
公开(公告)号： EP2307387A1公开(公告)日： 2011-04-13
- 发明人: AEBI, Johannes , BINGGELI, Alfred , GREEN, Luke , HARTMANN, Guido , MAERKI, Hans, P. , MATTEI, Patrizio , RICKLIN, Fabienne , ROCHE, Olivier
- 申请人： F. Hoffmann-La Roche AG
- 申请人地址： Grenzacherstrasse 124 4070 Basel CH
- 专利权人： F. Hoffmann-La Roche AG
- 当前专利权人： F. Hoffmann-La Roche AG
- 当前专利权人地址： Grenzacherstrasse 124 4070 Basel CH
- 代理机构： Salud, Carlos E.
- 优先权： EP08160534 20080716
- 国际公布： WO2010006938 20100121
- 主分类号： C07D241/08
- IPC分类号： C07D241/08 ; C07D243/08 ; C07D285/36 ; C07D401/06 ; C07D401/12 ; C07D403/06 ; C07D405/14 ; A61K31/4965 ; A61K31/497 ; A61K31/551 ; A61P9/10
摘要：
The invention is concerned with novel heterocyclyl compounds of formula (I); wherein A, X, Y
1 , Y
2 , Y
3 , R
3 , R
4 , R
5 , R
6 , R
7 , R
8 , R
9 , R
10 , m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
1 , Y
2 , Y
3 , R
3 , R
4 , R
5 , R
6 , R
7 , R
8 , R
9 , R
10 , m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.
公开/授权文献
信息查询
